{"id":"NCT01702428","sponsor":"GlaxoSmithKline","briefTitle":"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age","officialTitle":"Consistency Study of GSK Biologicals' Measles-mumps-rubella (MMR) Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Healthy Children 12 to 15 Months of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11-09","primaryCompletion":"2014-11-25","completion":"2015-04-16","firstPosted":"2012-10-08","resultsPosted":"2018-06-28","lastUpdate":"2019-11-25"},"enrollment":5016,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Rubella","Measles","Mumps"],"interventions":[{"type":"BIOLOGICAL","name":"Priorix","otherNames":["GSK Biologicals' live attenuated measles","mumps and rubella vaccine (GSK209762)"]},{"type":"BIOLOGICAL","name":"M-M-R II","otherNames":[]},{"type":"BIOLOGICAL","name":"Varivax","otherNames":[]},{"type":"BIOLOGICAL","name":"Havrix","otherNames":[]},{"type":"BIOLOGICAL","name":"Prevnar 13","otherNames":[]}],"arms":[{"label":"INV_MMR_L1 Group","type":"EXPERIMENTAL"},{"label":"INV_MMR_L2 Group","type":"EXPERIMENTAL"},{"label":"INV_MMR_L3 Group","type":"EXPERIMENTAL"},{"label":"COM_MMR Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate consistency in terms of the immune response to three different lots of GSK Biologicals' trivalent MMR vaccine manufactured to target potencies, and compare its immunogenicity to Merck \\& Co., Inc.'s MMR vaccine, which is approved for use in the United States (US).","primaryOutcome":{"measure":"Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value","timeFrame":"At Day 42","effectByArm":[{"arm":"INV_MMR _L1 Group","deltaMin":98.2,"sd":null},{"arm":"INV_MMR _L2 Group","deltaMin":98.9,"sd":null},{"arm":"INV_MMR _L3 Group","deltaMin":98.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":18},"locations":{"siteCount":90,"countries":["United States","Estonia","Finland","Mexico","Puerto Rico","Spain"]},"refs":{"pmids":["30849175"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":1239},"commonTop":["Irritability","Somnolence","Decreased appetite","Pyrexia","Rash"]}}